Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Study examines biomarkers for response to erlotinib in glioma

Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).

14 Jun 2005

Gene keeps neural cells on correct developmental path

23 May 2005

Gene keeps neural cells on correct developmental path

Embryonic stem cells with identical genomes grow into distinctive tissues, such as heart, bone, and brain. At one time, scientists believed the differences among cell types arose from various sets of genes switched on inside developing cells. Then, studies showed that adult neurons uniquely lack a protein that permanently turns off neuronal genes in the rest of the body's cells.

20 May 2005

Concurrent radiation, chemo, followed by surgery lengthens lung cancer patients' survival

Patients whose lung cancer has spread to the lymph nodes have a better chance of long-term survival if they receive combined modality therapy, such as concurrent radiation and chemotherapy followed by surgery, according to a study that Loyola University Health System’s Dr. Kathy S. Albain presented at the American Society of Clinical Oncology annual meeting.

18 May 2005

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Five-year data from a study evaluating the use of docetaxel (Taxotere) administered after cisplatin/etoposide chemotherapy plus radiation therapy demonstrate the best long-term survival rates reported in patients with locally advanced (Stage IIIB) non-small cell lung cancer (NSCLC).

16 May 2005

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).

16 May 2005

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Patients with a particular type of advanced lung cancer may have a new option based on data presented at the 2005 annual meeting of the American Society of Clinical Oncology showing that combining a drug that cuts off the cancer's blood supply with standard chemotherapy can shrink tumors and extend life.

15 May 2005

Hispanics have worse lung cancer survival rate

In a national population-based study of 16,036 lung cancer patients, Hispanics with curable stage I lung cancer had poorer lung cancer specific survival rates, as well as worse all-cause mortality, than a much larger group of white persons. Study results will appear in the second issue for May 2005 of the American Thoracic Society's peer-reviewed American Journal of Respiratory and Critical Care Medicine.

15 May 2005

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be more likely to respond to the drug gefitinib (Iressa), and this high gene copy number may be an effective predictor of gefitinib efficacy, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients

Lung cancer remains the leading cause of cancer deaths in the U.S., with half of those diagnosed at age 70 years or older. About 20 percent of patients with lung cancer will have small cell lung cancer (SCLC). In the past, SCLC progressed rapidly despite initial chemotherapy sensitivity and few patients survive three years.

25 Apr 2005

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Researchers at Fox Chase Cancer Center in Philadelphia have identified a subset of ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif.

20 Apr 2005

Clinical trial of gefitinib for advanced lung cancer closes early

Researchers have closed a randomized clinical trial comparing gefitinib (Iressa) vs. placebo following chemotherapy and radiation for patients with non-small cell lung cancer (NSCLC) that had spread only to nearby tissues or lymph nodes. Review of interim data indicated that gefitinib would not improve survival.

19 Apr 2005

Drug combo gives lung cancer patients longer life

Preliminary results from a large randomized clinical trial, sponsored by the National Cancer Institute (NCI), by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., have shown that patients with previously untreated advanced non-squamous non-small cell lung cancer who received bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Good results in new lung cancer treatment

Interim analysis of a Phase III study of Avastin (bevacizumab) with paclitaxel and carboplatin chemotherapies in first-line non-squamous, non-small cell lung cancer (NSCLC) met its primary goal of improving overall survival, or a reduction in the risk of death, compared to chemotherapy alone.

15 Mar 2005

Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients

Using Positron Emission Tomography in addition to Computed Tomography can reduce the amount of radiation exposure to normal tissue in some lung cancer patients

8 Mar 2005

Molecule from South American tree Quillaja, helps battle disease

The first synthesis of QS-21A, a medicinally important molecule that helps the body battle disease, has been achieved by chemists at the University of Illinois at Urbana-Champaign.

1 Mar 2005

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have found an explanation for why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa).

22 Feb 2005

Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS)

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.

10 Feb 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Small Cell Lung Cancer News and Research

Study examines biomarkers for response to erlotinib in glioma

Gene keeps neural cells on correct developmental path

Gene keeps neural cells on correct developmental path

Concurrent radiation, chemo, followed by surgery lengthens lung cancer patients' survival

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Hispanics have worse lung cancer survival rate

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Clinical trial of gefitinib for advanced lung cancer closes early

Drug combo gives lung cancer patients longer life

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Good results in new lung cancer treatment

Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients

Molecule from South American tree Quillaja, helps battle disease

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS)

Avastin available across Europe within the next few weeks

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News